Vonend O - Search Results

1

Effectiveness of eplerenone or spironolactone treatment in preserving renal function in primary aldosteronism.

Fourkiotis V, Vonend O, Diederich S, Fischer E, Lang K, Endres S, Beuschlein F, Willenberg HS, Rump LC, Allolio B, Reincke M, Quinkler M; Mephisto Study Group. Fourkiotis V, et al. Among authors: vonend o. Eur J Endocrinol. 2012 Dec 10;168(1):75-81. doi: 10.1530/EJE-12-0631. Print 2013 Jan. Eur J Endocrinol. 2012. PMID: 23033260 Clinical Trial.

2

Neuropeptide Y and ATP interact to control renovascular resistance in the rat.

Oberhauser V, Vonend O, Rump LC. Oberhauser V, et al. Among authors: vonend o. J Am Soc Nephrol. 1999 Jun;10(6):1179-85. doi: 10.1681/ASN.V1061179. J Am Soc Nephrol. 1999. PMID: 10361855

3

ATP release and degradation in the kidney: modulatory role of neuropeptide Y (NPY).

Rump LC, Vonend O, Oberhauser V. Rump LC, et al. Among authors: vonend o. Nephrol Dial Transplant. 1999;14 Suppl 4:48-9. doi: 10.1093/ndt/14.suppl_4.48. Nephrol Dial Transplant. 1999. PMID: 10463216 No abstract available.

4

ATP release in human kidney cortex and its mitogenic effects in visceral glomerular epithelial cells.

Vonend O, Oberhauser V, von Kügelgen I, Apel TW, Amann K, Ritz E, Rump LC. Vonend O, et al. Kidney Int. 2002 May;61(5):1617-26. doi: 10.1046/j.1523-1755.2002.00315.x. Kidney Int. 2002. PMID: 11967011 Free article.

5

Effects of angiotensin-(1-7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney.

Stegbauer J, Vonend O, Oberhauser V, Rump LC. Stegbauer J, et al. Among authors: vonend o. J Hypertens. 2003 Jul;21(7):1391-9. doi: 10.1097/00004872-200307000-00030. J Hypertens. 2003. PMID: 12817189

6

P2Y-receptors stimulating the proliferation of human mesangial cells through the MAPK42/44 pathway.

Vonend O, Grote T, Oberhauser V, Von Kügelgen I, Rump LC. Vonend O, et al. Br J Pharmacol. 2003 Jul;139(6):1119-26. doi: 10.1038/sj.bjp.0705358. Br J Pharmacol. 2003. PMID: 12871830 Free PMC article.

7

Moxonidine treatment of hypertensive patients with advanced renal failure.

Vonend O, Marsalek P, Russ H, Wulkow R, Oberhauser V, Rump LC. Vonend O, et al. J Hypertens. 2003 Sep;21(9):1709-17. doi: 10.1097/00004872-200309000-00021. J Hypertens. 2003. PMID: 12923404 Clinical Trial.

8

Angiotensin-(1-7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats.

Stegbauer J, Oberhauser V, Vonend O, Rump LC. Stegbauer J, et al. Among authors: vonend o. Cardiovasc Res. 2004 Feb 1;61(2):352-9. doi: 10.1016/j.cardiores.2003.11.017. Cardiovasc Res. 2004. PMID: 14736552

9

Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors.

Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J, Rump LC. Schwertfeger E, et al. Among authors: vonend o. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):455-61. doi: 10.1007/s00210-004-0930-9. Epub 2004 Apr 22. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15103451

10

Modulation of gene expression by moxonidine in rats with chronic renal failure.

Vonend O, Apel T, Amann K, Sellin L, Stegbauer J, Ritz E, Rump LC. Vonend O, et al. Nephrol Dial Transplant. 2004 Sep;19(9):2217-22. doi: 10.1093/ndt/gfh374. Epub 2004 Jul 20. Nephrol Dial Transplant. 2004. PMID: 15266031

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

92 results

Search Page

Filters